This issue of McDermott’s Healthcare Regulatory Check-Up highlights significant enforcement activity between May 21 and
June 20, 2022. Key updates include a case in which a California-based rheumatologist agreed to pay approximately $1 million to
settle allegations that he violated the False Claims Act (FCA) by charging Medicare for drugs not approved by the United States
Food and Drug Administration (FDA) and associated services related to the treatment of osteoarthritis pain. The Supreme Court
of the United States also overturned Medicare payment cuts applicable to 340B drugs in 2018 and 2019, finding that the US
Department of Health and Human Services (HHS) failed to carry out a required survey of hospital drug acquisition costs before
In addition to examining recent Office of Inspector General (OIG) advisory opinions, we provide an update on the No Surprises Act
and the first fines issued against hospitals for noncompliance with the price transparency rules that took effect in January 2021.
Finally, we take a look at recent Centers for Medicare & Medicaid Services (CMS) activity, including its recommendations for
Medicare Part B premium reexamination and a comment notice regarding the self-referral disclosure protocol.
A California-based rheumatologist agreed to pay approximately $1 million to settle allegations that he violated the FCA by charging
Medicare for non-FDA-approved drugs and associated services related to the treatment of osteoarthritis pain. The drugs...
You don't have permission to access "http://biz.chosun.com/en/en-policy/2026/05/13/2HN2WQNDIBDIHAYG2WCLNSLBYU/" on this server. Reference #18.9e033817.1778664023.2326d3f https://errors.edgesuite.n...